Label updates could lead to sig­nif­i­cantly im­proved out­comes for patients with multiple myeloma

Beerse, Belgium (Press Release) - Janssen-Cilag Inter­na­tional NV (Janssen) announced today that The Committee for Medical Products for Human Use (CHMP) of The European Medicines Agency (EMA) has granted a positive opinion on two variations relating to the use of VELCADE®.[1] VELCADE® is indicated for the treat­ment of multiple myeloma, a type of blood cancer.

The first recom­men­da­tion is for the use of VELCADE® (bor­tez­o­mib) as retreatment in adult patients who have pre­vi­ously responded to treat­ment with the same medicine.¹ The positive opinion re-enforces the ex­ist­ing data sup­porting the use of VELCADE® in this wider re­lapsed patient …

This year’s Congress of the European Hematology Association (EHA) is cur­rent­ly being held in Stockholm. It started earlier this week and will run through Sunday, June 16.

A substantial amount of myeloma-related research will be presented during the EHA meeting during both oral presentations and poster pre­sen­ta­tions.

This article summarizes some of the important myeloma-related findings that are expected to be presented during poster sessions today and to­mor­row. A previous article covered the key findings that will be pre­sented during oral pre­sen­ta­tions.

The studies covered in this article are primarily ones …

Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year.  The first education and poster sessions of the meet­ing will take place tomorrow, Friday, June 14.  Additional sessions of vari­ous kinds are scheduled for both days of the weekend, until the meet­ing ends early Sunday afternoon (European time).

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related dis­eases, in­clud­ing multiple myeloma.

The EHA meeting is …

This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago.

During the meeting, The Beacon pub­lished daily up­dates that provided over­views of the im­por­tant mul­ti­ple myeloma findings pre­sented during the meeting.

Now that the meeting has concluded, the focus shifts to the bigger picture: What were the key findings of the meeting? Were there re­­sults with im­medi­ate im­pli­ca­­tions for the treat­ment of mul­ti­ple myeloma?  Did the re­search at the meeting rep­re­sent a major step for­ward for myeloma patients, or …

This year’s American Society of Clinical Oncology (ASCO), which was held in Chicago, began on Friday and concluded on Tuesday.

Monday was the busiest day at the meeting with regard to myeloma re­search.  It featured a session of oral pre­sen­ta­tions in the morn­ing and a poster session in the afternoon.

This up­date summarizes the myeloma-related stud­ies pre­sented during the afternoon poster session, which was the final myeloma-related session of the meeting. An earlier article covered the findings from the oral pre­sen­ta­tions that were given in the morn­ing.

Most of the key …

This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.

Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that in­cluded eight talks about im­por­tant new myeloma-related research. A poster session in the afternoon in­cluded several posters about myeloma-related research.

This article summarizes the most im­por­tant findings from Monday's oral pre­sen­ta­tion session. A later article will cover the findings from the after­noon poster session.

The content in our daily updates is based on the …

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.

Sunday started with a poster session in which im­por­tant new re­search findings were summarized on posters dis­played throughout a large conference hall.

The stud­ies pre­sented during the session were on a wide variety of myeloma-related topics, in­clud­ing new treat­ments being devel­oped for myeloma, cur­rently used regi­mens, smol­der­ing mul­ti­ple myeloma, and findings on initial ther­apy.

Some of the posters in­cluded pre­lim­i­nary results from on­go­ing clin­i­cal trials.  Others described the design …